Shield Therapeutics PLC Investor Presentation

TIDMSTX

Shield Therapeutics PLC

21 December 2020

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

Investor Presentation

London, UK, 21 December 2020: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), announces that a recording of the online Company presentation, which was delivered live by Tim Watts, Chief Executive Officer on Wednesday 16 December 2020 is now available to watch back on the Company's website here: Investors Videos and Audio | Shield Therapeutics and on the Investor Meet Company platform at https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor. The Q&A has also been published following the meeting.

For further information please contact:

 
 Shield Therapeutics plc                             www.shieldtherapeutics.com 
 Tim Watts, CEO                                             +44 (0)20 7186 8500 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                    +44 (0)20 7418 8900 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                     +44 (0)20 7220 0500 
 
 
   Financial PR & IR Advisor 
 Walbrook PR                       +44 (0)20 7933 8780 or shield@walbrookpr.com 
                                          +44 (0)7980 541 893 / +44 (0)7584 391 
 Paul McManus/Lianne Cawthorne                                              303

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru(R) is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRATPBRTMTTBBLM

(END) Dow Jones Newswires

December 21, 2020 02:00 ET (07:00 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024